| Autor: |
Viehweger, Florian, Hoop, Jennifer, Tinger, Lisa-Marie, Bernreuther, Christian, Büscheck, Franziska, Clauditz, Till S., Hinsch, Andrea, Jacobsen, Frank, Luebke, Andreas M., Steurer, Stefan, Hube-Magg, Claudia, Kluth, Martina, Marx, Andreas H., Krech, Till, Lebok, Patrick, Fraune, Christoph, Burandt, Eike, Sauter, Guido, Simon, Ronald, Minner, Sarah |
| Předmět: |
|
| Zdroj: |
Biomedicines; May2024, Vol. 12 Issue 5, p957, 16p |
| Abstrakt: |
Androgen receptor (AR) is a transcription factor expressed in various normal tissues and is a therapeutic target for prostate and possibly other cancers. A TMA containing 18,234 samples from 141 different tumor types/subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. AR positivity was found in 116 tumor types including 66 tumor types (46.8%) with ≥1 strongly positive tumor. Moderate/strong AR positivity was detected in testicular sex cord-stromal tumors (93.3–100%) and neoplasms of the prostate (79.3–98.7%), breast (25.0–75.5%), other gynecological tumors (0.9–100%), kidney (5.0–44.1%), and urinary bladder (5.4–24.2%). Low AR staining was associated with advanced tumor stage (pTa versus pT2-4; p < 0.0001) in urothelial carcinoma; advanced pT (p < 0.0001), high tumor grade (p < 0.0001), nodal metastasis (p < 0.0001), and reduced survival (p = 0.0024) in invasive breast carcinoma; high pT (p < 0.0001) and grade (p < 0.0001) in clear cell renal cell carcinoma (RCC); and high pT (p = 0.0055) as well as high grade (p < 0.05) in papillary RCC. AR staining was unrelated to histopathological/clinical features in 157 endometrial carcinomas and in 221 ovarian carcinomas. Our data suggest a limited role of AR immunohistochemistry for tumor distinction and a prognostic role in breast and clear cell RCC and highlight tumor entities that might benefit from AR-targeted therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
